OBJECTIVES: Heavily treatment-experienced patients with good virological control could be at risk of virological failure on switching to a new regimen if pre-existing drug resistance is not taken into account. We examined whether genotyping based on cellular HIV-1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV-1 RNA during treatment with previous antiretroviral regimens. PATIENTS AND METHODS: All 169 patients enrolled in the Agence Nationale de Recherche sur le SIDA (ANRS) 138-intEgrase inhibitor MK_0518 to Avoid Subcutaneous Injections of EnfuviRtide (EASIER) trial had already received threeantiretroviral drug classes [nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)] and had plasmaHIV-1 RNA<400 copies/ml at baseline. The results of previous resistance genotyping of plasma HIV-1 RNA in individual patients were compared with those of resistance genotyping of whole-blood HIV-1 DNA at randomization. RESULTS: A median of 4 plasma RNA genotypes were available for the 169 patients. The median numbers of resistance mutations in HIV-1 RNA and DNA were, respectively, 5 and 4 for NRTIs, 2 and 1 for NNRTIs, and 10 and 8 for PIs. The difference was significant for all three drug classes (P=0.001). Resistance to at least one antiretroviral drug was detected exclusively in HIV-1 RNA or in DNA in 63% and 13% of patients for NRTI, 47% and 1% of patients for NNRTI, and 50% and 7% of patients for PI, respectively. CONCLUSION: This study shows that, among highly treatment-experienced patients on effective highly active antiretroviral therapy, resistance genotyping of HIV-1 DNA detects fewer resistance mutations than previous analyses of HIV-1 RNA. These results have implications for patient management and for the design of switch studies.
RCT Entities:
OBJECTIVES: Heavily treatment-experienced patients with good virological control could be at risk of virological failure on switching to a new regimen if pre-existing drug resistance is not taken into account. We examined whether genotyping based on cellular HIV-1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV-1 RNA during treatment with previous antiretroviral regimens. PATIENTS AND METHODS: All 169 patients enrolled in the Agence Nationale de Recherche sur le SIDA (ANRS) 138-intEgrase inhibitor MK_0518 to Avoid Subcutaneous Injections of EnfuviRtide (EASIER) trial had already received three antiretroviral drug classes [nucleoside reverse transcriptase inhibitor (NRTI), nonnucleoside reverse transcriptase inhibitor (NNRTI) and protease inhibitor (PI)] and had plasma HIV-1 RNA<400 copies/ml at baseline. The results of previous resistance genotyping of plasma HIV-1 RNA in individual patients were compared with those of resistance genotyping of whole-blood HIV-1 DNA at randomization. RESULTS: A median of 4 plasma RNA genotypes were available for the 169 patients. The median numbers of resistance mutations in HIV-1 RNA and DNA were, respectively, 5 and 4 for NRTIs, 2 and 1 for NNRTIs, and 10 and 8 for PIs. The difference was significant for all three drug classes (P=0.001). Resistance to at least one antiretroviral drug was detected exclusively in HIV-1 RNA or in DNA in 63% and 13% of patients for NRTI, 47% and 1% of patients for NNRTI, and 50% and 7% of patients for PI, respectively. CONCLUSION: This study shows that, among highly treatment-experienced patients on effective highly active antiretroviral therapy, resistance genotyping of HIV-1 DNA detects fewer resistance mutations than previous analyses of HIV-1 RNA. These results have implications for patient management and for the design of switch studies.
Authors: Anna Maria Geretti; Jose Luis Blanco; Anne Genevieve Marcelin; Carlo Federico Perno; Hans Jurgen Stellbrink; Dan Turner; Tuba Zengin Journal: Infect Dis Ther Date: 2022-08-01
Authors: Amy G Cutrell; Jonathan M Schapiro; Carlo F Perno; Daniel R Kuritzkes; Romina Quercia; Parul Patel; Joseph W Polli; David Dorey; Yongwei Wang; Sterling Wu; Veerle Van Eygen; Herta Crauwels; Susan L Ford; Mark Baker; Christine L Talarico; Marty St Clair; Jerry Jeffrey; C Thomas White; Simon Vanveggel; Kati Vandermeulen; David A Margolis; Michael Aboud; William R Spreen; Jan van Lunzen Journal: AIDS Date: 2021-07-15 Impact factor: 4.632
Authors: Anne Derache; Hyoung-Shik Shin; Maya Balamane; Elizabeth White; Dennis Israelski; Jeffrey D Klausner; Alexandra H Freeman; David Katzenstein Journal: PLoS One Date: 2015-01-30 Impact factor: 3.240
Authors: Elizabeth M Etta; Lufuno Mavhandu; Cecile Manhaeve; Keanan McGonigle; Patrick Jackson; David Rekosh; Marie-Louise Hammarskjold; Pascal O Bessong; Denis M Tebit Journal: AIDS Res Ther Date: 2017-07-27 Impact factor: 2.250
Authors: Andrea Arias; Pablo López; Raphael Sánchez; Yasuhiro Yamamura; Vanessa Rivera-Amill Journal: Int J Environ Res Public Health Date: 2018-08-09 Impact factor: 3.390
Authors: Natalia Stella-Ascariz; Rocio Montejano; María Martin-Vicente; Jesús Mingorance; Ignacio Pérez-Valero; José I Bernardino; Jose R Arribas Journal: Open Forum Infect Dis Date: 2016-02-19 Impact factor: 3.835